Laatste nieuws in biotech
AI Breakthrough Offers New Hope for Personalised Pancreatic Cancer Treatment
Amsterdam, Monday 9 March 2026
By analysing data from over 550,000 patients, a new AI tool now helps doctors select the most effective pancreatic cancer treatments, potentially sparing patients from unnecessary toxic therapies.
uniQure Faces US Securities Lawsuit
Amsterdam, Monday 2 March 2026
Amsterdam’s uniQure N.V. is facing a securities class action by DJS Law Group, spotlighting the growing legal challenges for Benelux firms listed in the United States. The class period is between 24 September 2025 and 31 October 2025.
Rapid Adoption of Novo Nordisk’s Weight Loss Pill Signals Market Shift
Alphen aan den Rijn, Friday 20 February 2026
Novo Nordisk’s oral Wegovy secured over 70% physician prescription rates in its first month, marking a pivotal shift from injectables and intensifying competition ahead of Eli Lilly’s anticipated 2026 launch.
BBB Appoints Strategist Henk Vermeer as Leader Following Van der Plas Resignation
The Hague, Friday 20 February 2026
Co-founder Henk Vermeer succeeds Caroline van der Plas as BBB leader, a strategic move that notably bypasses Vice Premier Mona Keijzer to consolidate the party’s parliamentary direction.
Strategic Report Urges Netherlands to Prioritise Biotech or Risk Economic Stagnation
The Hague, Monday 16 February 2026
Mirroring Draghi’s EU warnings, a new Dutch strategy reveals the biotech sector contributes just 1.1% to GDP, far behind Switzerland’s 5%, demanding immediate regulatory and financial reform.
VectorY Therapeutics Integrates AI Digital Twins to Accelerate ALS Clinical Trial
Amsterdam, Thursday 12 February 2026
VectorY collaborates with Unlearn to utilise AI-generated digital twins, creating prognostic patient forecasts to strengthen trial evidence and accelerate the development of their novel ALS genetic therapy.